A decade comparison of regulatory decision patterns for oncology products to all other non‐oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration
Abstract Consensus of regulatory decisions on the same Marketing Authorization Application (MAA) are critical for stakeholders. In this context, regulatory decision patterns from the Swissmedic (SMC), the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) were analyzed fo...
Saved in:
Main Authors: | Ulrich‐P. Rohr (Author), Mario Iovino (Author), Leonie Rudofsky (Author), Qiyu Li (Author), Stephanie Juritz (Author), Arunas Gircys (Author), Oliver Wildner (Author), Magda Bujar (Author), Claus Bolte (Author), Simon Dalla Torre di Sanguinetto (Author), Anita Wolfer (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency
by: Marc Maliepaard, et al.
Published: (2023) -
Pharmaceutical equivalence of oncology products marketed in Brazil
by: Marcus Augusto Lyrio Traple, et al.
Published: (2013) -
Pharmaceutical equivalence of oncology products marketed in Brazil
by: Marcus Augusto Lyrio Traple, et al.
Published: (2013) -
Potential Role of Natural Antioxidant Products in Oncological Diseases
by: Pasquale Marino, et al.
Published: (2023) -
On Productive Shame, Reconciliation, and Agency
Published: (2016)